Released Aug 13, 2014, after the close
10-Q filed Aug 14, 2014, 45 days after period end · 0001019687-14-003169
Q2 2014 · 10-Q
Revenue$6.87M$6.87M +24.2% vs Q2 2013+7.1% vs Q1 2014
Net Income-$1.35M-$1.35M N/M vs Q2 2013N/M vs Q1 2014
EPS Diluted-$0.02-$0.02 — vs Q2 2013N/M vs Q1 2014
Operating Income-$1,300,000N/M
Operating Cash Flowderived-$1,537,000N/M
Free Cash Flowderived-$1,700,000N/M
Margins · derived
Operating margin-18.9%−16.8 pt vs Q2 2013
Net margin-19.6%−17.8 pt vs Q2 2013
What the release said
The release
Same quarter
| Metric | Q2 2014 | Q2 2013 | Q2 2012 | Q2 2011 |
|---|---|---|---|---|
| Revenue | $6.87M | $5.53M | $6.02K | $6.07K |
| Net Income | -$1.35M | -$99.00K | -$633.00K | -$984.00K |
| EPS Diluted | -$0.02 | $0.00 | -$0.01 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR